Nanobodies against tumor necrosis factor-alpha
AssigneeAblynx N.V.
InventorEls Anna Alice Beirnaert
Life of this patent
Estimating the term…
Abstract
The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
Claims19
An isolated immunoglobulin variable domain that binds TNF-alpha comprising four framework regions (FR1 to FR4) and three complementarity determining regions (CDR1 to CDR3), wherein:
- a) CDR1 comprises:
- amino acid sequence TADMG (SEQ ID NO:
- 193);
- b) CDR2 comprises:
- amino acid sequence RISGIDGTTYYDEPVKG (SEQ ID NO:
- 261);
- and
- c) CDR3 comprises:
- amino acid sequence PRYADQWSAYDY (SEQ ID NO:
- 329).
An isolated immunoglobulin variable domain that binds TNF-alpha, wherein the immunoglobulin variable domain is a humanized variant of immunoglobulin variable domain NC55TNF_NC7 (SEQ ID NO:
- 125).
Dependencies are inferred from the claim text.